In a 22-1 vote, a panel advising the FDA on the future of popular diabetes drug Avandia chose to keep the drug on the market. The panel review came after several studies that Avandia caused more risk for cardiovascular problems in patients taking the drug.
Read more Avandia information here:
David Mendosa's Avandia sharepost.
- Font size
- Email This
- Bookmark
- Thank you for your input
- Save
- RSS
- Report Abuse









